772 related articles for article (PubMed ID: 31912280)
41. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
42. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
43. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
Jellinger KA
J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
[TBL] [Abstract][Full Text] [Related]
44. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
Colloby SJ; Williams ED; Burn DJ; Lloyd JJ; McKeith IG; O'Brien JT
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1176-85. PubMed ID: 15931516
[TBL] [Abstract][Full Text] [Related]
45. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
46. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
47. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
48. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
49. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Jellinger KA; Korczyn AD
BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
[TBL] [Abstract][Full Text] [Related]
50. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
[TBL] [Abstract][Full Text] [Related]
51. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
52. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes.
Kalaitzakis ME; Walls AJ; Pearce RK; Gentleman SM
Neurobiol Dis; 2011 Feb; 41(2):377-84. PubMed ID: 20951207
[TBL] [Abstract][Full Text] [Related]
53. Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease.
Ibanez L; Bahena JA; Yang C; Dube U; Farias FHG; Budde JP; Bergmann K; Brenner-Webster C; Morris JC; Perrin RJ; Cairns NJ; O'Donnell J; Álvarez I; Diez-Fairen M; Aguilar M; Miller R; Davis AA; Pastor P; Kotzbauer P; Campbell MC; Perlmutter JS; Rhinn H; Harari O; Cruchaga C; Benitez BA
Acta Neuropathol Commun; 2020 Nov; 8(1):196. PubMed ID: 33213513
[TBL] [Abstract][Full Text] [Related]
54. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.
Shimada H; Shinotoh H; Hirano S; Miyoshi M; Sato K; Tanaka N; Ota T; Fukushi K; Irie T; Ito H; Higuchi M; Kuwabara S; Suhara T
Mov Disord; 2013 Feb; 28(2):169-75. PubMed ID: 23225334
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
[TBL] [Abstract][Full Text] [Related]
56. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.
Mandal PK; Pettegrew JW; Masliah E; Hamilton RL; Mandal R
Neurochem Res; 2006 Sep; 31(9):1153-62. PubMed ID: 16947080
[TBL] [Abstract][Full Text] [Related]
57. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.
Stefani A; Brusa L; Olivola E; Pierantozzi M; Martorana A
J Neural Transm (Vienna); 2012 Jul; 119(7):861-75. PubMed ID: 22622365
[TBL] [Abstract][Full Text] [Related]
58. Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice.
Lilamand M; Clery J; Vrillon A; Mouton-Liger F; Cognat E; Gaubert S; Hourregue C; Martinet M; Dumurgier J; Hugon J; Bouaziz-Amar E; Paquet C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362275
[TBL] [Abstract][Full Text] [Related]
59. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
[TBL] [Abstract][Full Text] [Related]
60. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]